My goal is to develop a model-based dose decision support tool that will suggest doses that minimize the sum of the risks of death by disease and by drug for chronic myeloid leukemia (CML) patients. Best doses will drive CML loads down rapidly at high loads posing high progression risks and as loads lower to ones with low progression risks, they will drive loads down more slowly to focus instead on lowering toxicity risks.